Finding a liability-free space in which personalized medicine can bloom

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 4, 2007, Pages 461-465

  Evans, B J ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG MANUFACTURE; GENETICS; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; LAW SUIT; LEGAL LIABILITY; MEDICAL LIABILITY; MEDICAL PRACTICE; NEGLIGENCE; PERSONALIZED MEDICINE; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SCHOOL; SCREENING TEST;

BIOLOGICAL MARKERS; CONFLICT OF INTEREST; DRUG THERAPY; ETHICS, CLINICAL; GENETIC PRIVACY; GENETIC SCREENING; GOVERNMENT REGULATION; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LEGISLATION, DRUG; LIABILITY, LEGAL; PATIENT SELECTION; PHARMACOGENETICS; UNITED STATES;

EID: 34548684786     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100335     Document Type: Review

References (44)

1. Rothstein, M.A. Liability issues in pharmacogenomics. LA Law Rev. 66, 117-124 (2005).
2. Marchant, G.E., Milligan, R.J. & Wilhelmi, B. Legal pressures and incentives for personalized medicine. Future Med. 3, 391-397 (2006).
3. Danzon, P.A. Alternative liability regimes for medical injuries: evidence from simulation analysis. J. Risk Insur. 61, 219 (1994).
4. Localio, A.R. et al. Relation between malpractice claims and adverse events due to negligence: results of the Harvard Medical Practice Study III. N. Engl. J. Med. 325, 245-251 (1991).
5. Liang, B.A. Promoting patient safety through reducing medical error: a paradigm of cooperation between physician, patient, and attorney. South. Ill. Univ. Law J. 24, 541 (2000).
6. Ben-Shahar, O. How Liability Distorts Incentives of Manufacturers to Recall Products, University of Michigan John M. Olin Center for Law & Economics (2005) 〈http://www.law.michigan.edu/ centersandprograms/olin/ papers.htm〉.
7. Evans, B.J. & Flockhart, D.A. The unfinished business of US drug safety regulation. Food Drug Law J. 61, 45-63 (2006).
8. Jost, T.S. Our broken healthcare system and how to fix it: an essay on health law and policy. Wake Forest Law Rev. 41, 537-618 (2006).
9. Roses, A.D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5, 645-656 (2004).
10. Brody, H. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry 189-190, 232-233 (Rowman & Littlefield: Lanham, MD, 2007).
11. Mintzes, B. et al. How does direct-to-consumer advertising (DTCA) affect prescribing? a survey in the primary care environment with and without legal DTCA. CMAJ 169, 405-412 (2003).
12. Wu, A.W. Handling hospital errors: is disclosure the best defense? Ann. Intern. Med. 131, 970-972 (1999).
13. Mazor, K.M. et al. Health plan members' views about disclosure of medical errors. Ann. Intern. Med. 140, 409-418 (2004).
14. Brennan, T.A. et al Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. N. Engl. J. Med. 324, 370-376 (1991).
15. US Department of Health and Human Services. Food and Drug Administration, Guidance for Industry: Pharmacogenomic Data Submissions (March 2005).
16. Calabro, S. Breaking the shield of the learned intermediary doctrine: placing blame where it belongs. Cardozo Law Rev. 25, 2241-2316 (2004).
17. Restatement (Second) of Torts §402A, cmt. k (1977).
18. Kane, D.S. Annotation: construction and application of the learned intermediary doctrine, 57 A.L.R. 5th 1, §2A (1998) updated through 2004.
19. Sharp, L.A. Annotation: malpractice: physician's liability for injury or death resulting from side effects of drugs intentionally administered to or prescribed for a patient, 57 A.L.R. 5th 433, §2[a] (1997) updated through 2004.
20. Curran, W.J., Hall, M.A., Bobinski, M.A. & Orentlicher, D.A. Health Care Law and Ethics 5th edn. 314-337 (Aspen Law & Business, New York, 1998).
21. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Special Report: Medical Necessity in Private Health Plans (2003).
22. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Special Report: Medical Necessity in Private Health Plans (2003).
23. US Census Bureau. Income, Poverty, and Health Insurance Coverage in the United States: 2005 (August 2006, updated 23 March 2007) 〈http://www.pubdb3.census.gov/macro/032006/health/ h01_001.htm〉.
24. Pub. L. 93-406, 2 September 1974, 88 Stat. 829; codified at 29 USC §1001 et seq. (2007).
25. Borzi, P.C. ERISA Health Plans: Key Structural Variations and their Effect on Liability (George Washington University Center for Health Services Research and Policy, September 2005).
26. Kaiser Family Foundation/Health Research and Educational Trust. Employer Health Benefits 2006 Annual Survey 〈http://www.kff.org/ insurance/7527/upload/7527.pdf〉.
27. Employee Benefits Research Institute. Facts from EBRI: Typical Health Benefit Package in Private Industry (April 2006) see 2005 data.
28. 542 U.S. 200 (2004).
29. Ondraski, P.J. & Serron, E.G. Managed care and the edges of ERISA preemption. American Law Institute - American Bar Association Continuing Legal Education SM010, 205-284 (2007).
30. Mills, L.R. & Pautler, R.J A third form of ERISA preemption: Aetna Health Inc. v. Davila. Benefits Law J. 18, 61-70 (2005).
31. ERISA §502(a)(1)(B), 29 USC §1132(a)(1)(B) (2007).
32. Davila, 542 U.S. at 222 (Ginsburg, J., concurring) (2004).
33. Di Felice v. Aetna US Healthcare, 346 F.3d 442, 453 (C.A.3 2003) (Becker J. concurring).
34. Note, New evidence on the presumption against preemption: an empirical study of congressional responses to Supreme Court preemption decisions. Harvard Law Rev. 120, 1604-1626 (2007).
35. ERISA §502(a), 29 USC §1132(a) (2007).
36. Langbein, J.H. What ERISA means by 'equitable': the Supreme Court's trail of error in Russell, Mertens, and Great-West. Columbia Law Rev. 103, 1317-1366 (2003).
37. Williams, E.D., Sarata, A.K. & Redhead, C.S. Genetic Discrimination: Overview of the Issue and Proposed Legislation (Congressional Research Service, RL33903, 7 March 2007).
38. Clayton, E.W. Ethical, legal, and social implications of genomic medicine. N. Engl. J. Med. 349, 562-569 (2003).
39. H.R. 493; S. 358 (110th Congress, 2007).
40. Report to Accompany S. 358, No. 110-48 (10 April 2007).
41. ERISA §§ 514(a), (b)(2)(A), (b)(2)(B), 29 U.S.C. §1144(a), (b)(2)(A), (b)(2)(B) (2007).
42. Kaiser Family Foundation. Employer Health Benefits 2006 Annual Survey, Section 10 (Plan Funding), Exhibit 10.2 〈http://www.kff.org/ insurance/7527/index.cfm〉.
43. Teagarden, J.R. Genomics and personalized medicine in pharmacy benefits and specialty pharmacy. Pharmaceutical Care Management Association Fourth Annual Specialty Pharmacy Symposium, 16-17 April 2007 〈http://www. pcmanet.org/events/2007/ SpecRxSym07.htm#Presentations〉.
44. Clinical Data, Inc.. Press Release: Clinical data and PharmaCare sign landmark pharmacogenomics testing agreement: first agreement of its kind facilitates implementation of pharmacogenomics testing to improve patient care (14 September 2006) 〈/http://investor.clda.com/ releasedetail.cfm? releaseid=211149〉.